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Abstract 28 
 29 
Human onchocerciasiscommonly known as river blindnessis one of the most 30 
devastating yet neglected tropical diseases, leaving many millions in Sub-Saharan 31 
Africa blind and/or with chronic disabilities. Attempts to eliminate onchocerciasis, 32 
primarily through the mass drug administration of ivermectin remains challenging and 33 
has been heightened by the recent news that drug-resistant parasites are developing in 34 
some populations after years of drug treatment. Needed, and needed now, in the fight 35 
to eliminate onchocerciasis are new tools, such as preventive and therapeutic vaccines. 36 
This review summarizes the progress made to advance the onchocerciasis vaccine 37 
from the research lab into the clinic.  38 
 39 
 40 
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Why a vaccine against Onchocerca volvulus is needed 43 
 44 
Human onchocerciasis caused by Onchocerca volvulus and spread by the bite of 45 
infected Simulium black flies remains one of the most important neglected tropical 46 
diseases (NTDs).  Recent estimates from the Global Burden of Disease Study 2015 47 
indicate that approximately 15.5 million people currently live with onchocerciasis, 48 
including 12.2 million people with Onchocerca skin disease (OSD) and 1.025 million 49 
with vision loss (river blindness) [1]. Almost everyone severely affected with OSD and 50 
river blindness lives in Sub-Saharan Africa or Yemen in the Middle East.  51 
 52 
Through programs of mass drug administration (MDA) with ivermectin, tremendous 53 
strides have been made in reducing the global prevalence of onchocerciasis. 54 
Transmission has been nearly eliminated in Latin America, while globally there has 55 
been a 29 percent reduction in the prevalence of onchocerciasis since 2005 [1]. 56 
However, it remains unlikely that onchocerciasis can be eliminated as a public health 57 
problem entirely through ivermectin mass treatments. The reasons for this observation 58 
have been reviewed recently, and include the inability to implement large-scale 59 
treatment programs in areas that are co-endemic for loiasis, and the potential for 60 
emerging anthelminthic drug resistance [2]. Recent genome-wide analyses revealed 61 
genetic variation that significantly differentiated O. volvulus parasites that are good 62 
responders to treatment with ivermectin to O. volvulus parasites that are sub-optimal 63 
responder and taken from individuals in Ghana and Cameroon that have experienced 64 
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repopulation of the skin microfilariae earlier/more extensively after ivermectin treatment 65 
than expected [3]. 66 
 67 
In addition, disease modeling studies show that transmission interruption and 68 
elimination will require routine and regular quantum reductions in O. volvulus 69 
microfilariae in the skin and subcutaneous tissues following each round of MDA, but 70 
such targets are seldom achieved [2]. The African Programme for Onchocerciasis 71 
Control predicted in 2015 that to achieve elimination 1.15 billion treatments will have 72 
needed to be administered until 2045 [4]. Such estimates indicate that onchocerciasis 73 
may not be eliminated for decades using current approaches.  74 
 75 
To accelerate elimination and advance towards the major targets of the 2012 London 76 
Declaration for NTDs 77 
(http://unitingtocombatntds.org/sites/default/files/document/london_declaration_on_ntds.78 
pdf), there is an effort to develop new and improved control tools. These include better 79 
diagnostics, small-molecule drugs and vaccines that can improve surveillance and 80 
achieve longer and more sustained reductions in host microfilarial loads.  There is also 81 
a need for better safety profiles for interventions used in loiasis co-endemic areas of 82 
Africa.  Individuals who have high blood levels of Loa loa microfilariae, a filarial infection 83 
that usually does not cause clinical disease, and receive ivermectin as part of the MDA 84 
programs to eradicate lymphatic filariasis and onchocerciasis may develop a severe 85 
inflammatory reaction that can result in encephalopathy, and rarely death. In 2015, an 86 
international consortium launched a new global initiative, known as TOVA – The 87 
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Onchocerciasis Vaccine for Africa [2]. TOVA is evaluating and pursuing vaccine 88 
development as a complementary control tool. Briefly, TOVA is primarily using 89 
recombinant proteins and novel adjuvant platforms, with the goal to meet at least one of 90 
the desired target product profiles (TPP). The TPP either relies on a preventive vaccine 91 
for children under the age of five who have not yet had access to MDA with ivermectin, 92 
or a therapeutic vaccine for both adults and children with onchocerciasis (Table 1) [2]. 93 
The efforts to develop an effective, safe, and logistically feasible vaccine against 94 
onchocerciasis builds on the evidence of protective immunity achieved using live 95 
attenuated vaccines. Immunization with irradiated larvae typically achieves ~70% 96 
protection in laboratory settings [5-9], but such vaccines are not feasible for mass 97 
human immunization on safety, logistical, and economic grounds. Current efforts to 98 
develop a subunit vaccine, such as confirmatory vaccine trials in large-animal models, 99 
modeling studies, and future clinical trials will build the necessary body of evidence to 100 
allow for the selection of the best TPP.  The TPP presented in Table 1 was based in 101 
part on mathematical modelling that explored the potential influence of a prophylactic 102 
vaccination program on infection resurgence in areas where local elimination has been 103 
successfully achieved [10]. It assumed based on efficacy results in animal models of an 104 
initial prophylactic efficacy of 50%, and an initial therapeutic efficacy of 90%. The 105 
vaccine was assumed to target 1 to 5 year olds based on the age range included in the 106 
Expanded Programme on Immunization. The modelling indicated that an onchocerciasis 107 
vaccine would have a beneficial impact in onchocerciasis-loiasis co-endemic areas, 108 
markedly reducing microfilarial load in the young (under 20 yr) age groups. The TPP for 109 
therapeutic vaccines is still hypothetical as it assumes that it will be safe to target 110 
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immunologically residual microfilariae in young and adult population living in endemic 111 
regions that went through many years of MDA with ivermectin. 112 
 113 
Here, we provide a perspective of the importance of a rational design for the discovery 114 
and antigen selection process before embarking into advanced vaccine development of 115 
the onchocerciasis vaccine with a review of the current advancements and progress on 116 
the TOVA global initiative. Finally, we provide a prospective of how new technologies 117 
and artificial intelligence can catalyze and accelerate the evaluation and selection of 118 
suitable vaccine candidates leading to a greater chance of their translation into safe and 119 
efficacious human vaccines. 120 
 121 
Discovery and evaluation of the first generation vaccine candidate antigens 122 
  123 
Considerable effort has been expended in the 1990s on the identification of parasite 124 
molecules, primarily proteins, which induce a protective immune response in humans 125 
and in the available animal models of onchocerciasis. Anti-L3 protective immunity within 126 
the O. volvulus endemic population have been described in two populations: (1) 127 
immunity that impedes the development of a patent infection (microfilaria positive) in the 128 
putatively immune (PI) individuals (i.e., individuals that had no clinical manifestations of 129 
the disease, even though they lived for at least 10 years within regions where 130 
onchocerciasis is endemic and were exposed to high transmission rates of infection); 131 
and (2) concomitant immunity that develops in the patently infected individuals with 132 
increasing age and which is independent of the immune responses that are induced by 133 
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the adult worms and microfilaria associated with patent infection [11]. Protective 134 
immunity against the infective larvae was also shown in a mouse model employing O. 135 
volvulus L3 in diffusion chambers; a significant reduction of ~50% in the survival of 136 
larvae was obtained in mice immunized with normal, irradiated or freeze-thaw-killed L3 137 
[5]. 138 
 139 
Two basic strategies were used to identify and clone O. volvulus target vaccine 140 
antigens: (1) Exploitation of the potential involvement of antibodies in protective 141 
immunity by immunoscreening various O. volvulus cDNA libraries to identify target 142 
proteins. The success of the immunoscreening effort relied mostly on the source and 143 
specificity of the immune sera from human or animal hosts and, hence, was done 144 
mostly with serum samples from individuals identified as putatively immune. In addition, 145 
sera from vaccinated or immune animals (chimpanzees, mice or cows), polyclonal 146 
antibodies raised against O. volvulus infective stage larvae also called L3, or 147 
monoclonal antibodies developed against specific parasite-antigens, were used to 148 
screen the cDNA libraries. Initially cDNA libraries constructed from adult worm stages of 149 
O. volvulus were used and later cDNA libraries constructed from O. volvulus larval 150 
stages (L3, molting L3 and fourth-stage larvae or L4) were used. Altogether, out of 26 151 
recombinant antigens that were identified by immunoscreening and tested in the O. 152 
volvulus mouse model, 12 induced partial but significant protection (39–69%) in the 153 
presence of block copolymer, alum or Freund’s complete adjuvant [11-13]. (2) 154 
Identification and isolation of molecules thought to be essential during the infection 155 
process. These molecules would include proteins with vital metabolic functions or 156 
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defense properties, which would permit the parasite to survive in immunocompetent 157 
hosts. Targeting such molecules as vaccine candidates, would block or interfere with 158 
the establishment of the parasite in the host. In addition, antigens that are not normally 159 
seen by the host, but that are nevertheless accessible to host immune-effector 160 
molecules and cells, the ‘hidden antigens’, were also thought to be potentially useful as 161 
vaccine targets [14]. The identification of the genes and isolation of the encoding 162 
proteins of interest was achieved by one or multiple of the following methods: a) 163 
screening cDNA libraries using a heterologous probes [15]; b) amplification by PCR 164 
using degenerate primers and cloning strategies [15]; c) purification of the proteins from 165 
secreted products of larval stages followed by partial amino acid sequencing and 166 
molecular cloning [16]; or d) identification of the genes of interest by searching the O. 167 
volvulus expressed sequence tag (EST) database or the EST databases generated by 168 
the Filarial Genome Project [17]. Out of 18 recombinant antigens that have been cloned 169 
using these strategies and that were tested in the O. volvulus mouse model, four (Ov-170 
ALT-1, Ov-CHI-1, Av-ABC and Av-UBI) induced partial but significant protection. Of 171 
these, Av-ABC and Av-UBI were cloned from the rodent filarial parasite 172 
Acanthocheilonema viteae and were protective in the presence of alum or Freund’s 173 
complete adjuvant, as was Ov-ALT-1. In addition, chitinase, Ov-CHI-1, effectively 174 
induced protection using DNA immunization [18]. The Onchocerca homologue of Av-175 
ABC has not been studied yet, whereas the Av-UBI of A. viteae is completely identical 176 
to Ov-UBI. 177 
 178 
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The characteristics of the parasite proteins corresponding to the above protective 179 
recombinant O. volvulus antigens have been described in detail previously [12, 13, 19]. 180 
Eight of the proteins, Ov-ALT-1, Ov-B8, Ov-RAL-2, Ov-B20, OI5/OI3, Ov-CHI-1, Ov-181 
RBP-1 and Ov-103 are parasite specific antigens, whereas Ov-ASP-1 is a member of 182 
the vespid venom allergen-like protein family [20]. Six of the protective proteins are 183 
homologues to recognized proteins of higher organisms. Thus, Ov-CPI-2 184 
(onchocystatin), Ov-TMY-1 (tropomyosin), Ov-FBA-1 (aldolase), Ov-CAL-1 (calponin), 185 
Av-ABC (ATP binding cassette protein transporter) and Av-UBI (ubiquitin) have 32, 31, 186 
69, 42, 71 and 98% amino-acid identity, respectively, with human proteins. An important 187 
concern associated with vaccine antigens belonging to conserved gene families (e.g. 188 
enzymes, muscle proteins) is the risk of cross-reactions with host or environmental 189 
antigens. Eight antigens were also cloned from a very close relative of O. volvulus, O. 190 
ochengi, and used together to vaccinate cattle in the only field trial of a recombinant 191 
onchocerciasis vaccine performed to date [21]. These eight antigens included 192 
representatives from the parasite-specific [Oo-ALT-1, Oo-B8, Oo-RAL-2, Oo-B20 and 193 
Oo-FAR-1 (homolog of Ov-RBP-1)] as well as the highly conserved (Oo-TMY-1 Oo-194 
FBA-1, and Oo-CPI-2) protein groups. The multivalent vaccine induced statistically 195 
significant protection also against patency (microfilaridermia), but did not significantly 196 
reduce adult worm burden [22].  197 
 198 
Since the above described studies, only one additional antigen with protective 199 
properties, Ov-GAPDH, which was cloned using immunoscreening, has been recently 200 
reported [23]. Thus out of a total of 16 vaccine candidates, 12 were identified by 201 
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immunoscreening and 4 were identified using other approaches as illustrated in Figure 202 
1. Below we will describe the 8 vaccine candidates chosen to be studied more in depth 203 
for their ability to insure protection against infection. 204 
 205 
Evaluation and selection of the best vaccine candidates for a prophylactic 206 
vaccine using two small animal models 207 
 208 
Humans are the only definitive hosts of O. volvulus. Therefore, one of the significant 209 
challenges towards the development of a vaccine against onchocerciasis has been the 210 
absence of suitable small animal models that support the life-cycle of the parasite 211 
(Fig. S1). To overcome this obstacle, we adopted a dual-model screening system.  In 212 
the first model, O. volvulus L3 within diffusion chambers  constructed from 14 mm Lucite 213 
rings covered with 5.0 µM pore-size membranes are implanted in a subcutaneous 214 
pocket on the rear flank of mice [24]. This model has the advantages of using the target 215 
human parasite and allows the unique analysis of the host molecules and cells found 216 
within the parasite microenvironment. In addition, dissection of the mechanism of 217 
immunity induced by the vaccine can be accomplished with the plethora of reagents and 218 
assays designed for murine studies. A significant disadvantage of the mouse diffusion 219 
chamber model is that the parasites will only develop for a limited time in mice and thus 220 
adult worms and microfilariae do not develop. To overcome this limitation, we tested in 221 
parallel a second system, the Brugia malayi-gerbil model of lymphatic filariasis, using 222 
homologues of promising O. volvulus antigens. Injection of L3 subcutaneously in this 223 
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model allows for examination of vaccine efficacy following the natural migration of 224 
developing stages of parasites and their maturation to adult stages [25].   225 
 226 
From the pipeline of potential candidate antigens (Fig. 1), fifteen proteins were 227 
evaluated in previous studies using the mouse-Onchocerca model and identified as 228 
being able to induce partial protection following vaccination [13]. To select the most 229 
promising protective antigens for the early pre-clinical process development a scoring 230 
system was developed that allowed ranking these 15 antigens based on their other 231 
known characteristics (reviewed in ref [13]), and to select eight vaccinate candidate for 232 
more extensive studies. All the 15 O. volvulus protective antigens in the O. volvulus - 233 
mouse model were given a score of 1.0 (Supplement Table 1). The added scoring was 234 
based on the following criteria: (1) score 0.2 was given to those that are nematode or 235 
parasite specific with or without known function (for example Ov-CPI-2 (cystatin), Ov-236 
RBP-1 (retinoid binding protein) or Ov-CHI-1 (chitinase); (2) score 0.2 was given to 237 
those in which localization of the corresponding native proteins in L3 and/or mL3 by 238 
immunoelectron microscopy was in one or more regions that are also recognized by 239 
antibodies from protected humans and/or also from xL3 immunized and protected mice 240 
[11]; (3) score 0.2 was given to those being recognized by antibodies from protected 241 
humans (PI and INF with concomitant immunity) and/or animal models after 242 
immunization with xL3 (cattle, chimpanzees, mice); (4) score 0.2 was given to those 243 
being abundantly expressed in L3 and/or mL3, which indirectly indicates that the 244 
corresponding translated proteins are important for the parasite during the initial phases 245 
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of the Ov infection; and (5) score 0.2 was given to those where studies have shown the 246 
ability of antibodies targeting the parasite antigen to kill larvae in vitro.  247 
 248 
In addition, we have added two more criteria that are based on more recent published 249 
and unpublished studies and thus provide added support for the selection of these 8 250 
antigens for our proposed preclinical studies. A score of 1.0 was given to those (for 251 
examples Ov-ALT-1, Ov-CPI-2, Ov-RAL-2, chitinase, Ov-RBP-1 and Ov-B20) whose 252 
homologues have been shown to also induce protection in other filariae host–parasite 253 
systems [26-36].  Moreover, A score of 1.0 was given to those (Ov-ASP-1, Ov-103, Ov-254 
CPI-2 , Ov-RAL-2 ) having homologues in other nematode host–parasite systems that 255 
have been shown to be able to induce reduction in worm burden or other protective 256 
measures against hookworm infection in dogs and Ascaris in pigs [37-44]. Based on this 257 
rational innovative scoring system we have selected the top ranking 8 Ov protective 258 
antigens (Ov-CPI-2, Ov-ALT-1, Ov-RAL-2, Ov-ASP-1, Ov-103, Ov-RBP-1, Ov-CHI-1 259 
and Ov-B20) for which we propose to conduct extensive preclinical evaluation and 260 
further selection. Those selected are ranked between a total score of 4.0 to 2.6 261 
(Supplement Table 1). Those of the original 15 rOvAgs that were not selected were only 262 
ranked at a total score of 1.0 to 1.6.  263 
 264 
The eight selected O. volvulus proteins and the B. malayi homologues were expressed 265 
in both bacterial (Escherichia coli) and eukaryotic (Pichia) expression systems. In the 266 
presence of the adjuvant alum, the recombinant Ov-103 and Ov-RAL-2 proteins, 267 
together with their Bm-103 and Bm-RAL-2 homologues emerged as the most promising 268 
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candidates in each animal model, validating the robustness of our selection and 269 
prioritization process. Combination of these two antigens by either co-administration 270 
vaccine strategies or single injections using a recombinant fusion protein vaccine 271 
induced enhanced levels of protective immunity, demonstrating that the antigens could 272 
act synergistically in both systems [45, 46].  Furthermore, these co-administered 273 
molecules or the fusion proteins reduced embryogenesis in B. malayi females, 274 
suggesting a potential impact also on microfilaremia and transmission [46].    275 
 276 
Various adjuvants were evaluated and compared for their ability to improve efficacy by 277 
enhancing the killing of O. volvulus in diffusion chambers implanted in mice. Only 278 
adjuvants that induced Th2 responses, as determined by cytokine profiles, were 279 
effective at enhancing the vaccine efficacy, consistent with reports showing that IL-4, IL-280 
5, and functional eosinophils are necessary for the development of adaptive immunity in 281 
mice immunized with irradiated O. volvulus larvae [47-49], and the Litomosoides 282 
sigmodontis murine model [50-54]. Co-administration of both of the O. volvulus antigens 283 
enhanced parasite killing as compared to single antigen immunizations, with all of the 284 
adjuvants inducing Th2 responses. Antigen specific IgG1 was the dominant antibody 285 
isotype that developed in protected immunized mice. Based on chemokine levels within 286 
the diffusion chambers, it appears that eosinophils, macrophages and neutrophils 287 
participate in the killing mechanism. These findings suggest that the mechanism of 288 
protective immunity induced by the two O. volvulus antigens is multifactorial with roles 289 
for cytokines, chemokines, antibody and specific effector cells [55]. This observation 290 
was confirmed in the B. malayi–gerbil model, where it was demonstrated that serum 291 
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from gerbils immunized with the two B. malayi antigens on alum, killed the parasites in 292 
vitro, in collaboration with peritoneal exudate cells [46].  293 
 294 
Thus, based on the two model systems, O. volvulus in mice and B. malayi in gerbils, an 295 
effective two-antigen vaccine against O. volvulus has been identified. It consists of the 296 
proteins Ov-103 and Ov-RAL-2, administered with an adjuvant that induces Th2 297 
responses. Immunization with both antigens enhanced the protective immune response 298 
and the mechanism of protective immunity appears to be antibody and effector cell 299 
dependent, in both model systems.   300 
 301 
As mentioned above a third small animal model, the L. sigmodontis-BALB/c mouse 302 
model, has been developed and used for studying anti-filarial immunity and vaccines 303 
[56, 57]. This model also allows full development of the infective larvae to adult worms 304 
producing circulating microfilariae. It will be worthwhile to incorporate this third model 305 
into future efficacy pipeline studies and validate the L. sigmodontis homologous of the 306 
O. volvulus vaccine candidates also in this filarial infection model in mice. 307 
 308 
The need for a rational and efficient process to generate a robust pipeline of 309 
second generation vaccine candidate antigens  310 
 311 
The disappointing results obtained many times during human proof of concept clinical 312 
trials, continue to highlight the challenges and limitations of how to best predict whether 313 
a vaccine candidate translates successfully from animal testing into humans [58, 59]. 314 
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 315 
Many articles call for a change in paradigm from an empirical development strategy to a 316 
rational vaccine design [60-62]. Amongst the parameters driving decisions during the 317 
development of new vaccine targets, the current consensus is that antigen selection 318 
and optimization represents the foundation in vaccine design. In addition, it is essential 319 
to have available appropriate preclinical models, but it is also crucial to have optimal 320 
vaccine formulations, adjuvants and delivery strategies. These are essential elements to 321 
target the appropriate immune mechanisms of protection [63]. This is especially 322 
important when developing vaccines for infectious diseases, such as for onchocerciasis, 323 
because unfortunately scientific advances and tools are still trailing and there is also a 324 
need for safety and efficacy studies to be done more quickly, with more certainty and at 325 
lower costs.   326 
 327 
For example, strategies to identify the ideal Onchocerca vaccine candidate antigens can 328 
rely on selection processes based on the knowledge of candidates inducing effective 329 
immune responses, identifying antibody-based epitopes via computational prediction 330 
tools, down-selection of candidates based on predictions of sequences that could 331 
induce immunopathology or allergy, and continuous assessment of parasite molecules 332 
by structural biology and stability assessments. Hence, systems biology approaches 333 
continue to lead the efforts seeking better understanding of the mechanisms of 334 
protection and safety of vaccines [61]. 335 
 336 
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Considerable efforts have also been done in the area of novel adjuvant development. 337 
Subunit vaccines need help with secondary molecules modulating the immune 338 
responses. TOVA Initiative is also incorporating into the development path the 339 
evaluation of other adjuvants besides the traditional phosphate or hydroxide salts of 340 
aluminum such as oil-in-water emulsions and synthetic toll-like receptor agonists [62]. 341 
The objective is to select adjuvants that facilitate the most effective response, while in 342 
parallel investigate their optimized use, route and molecular mechanism. 343 
 344 
Selecting and evaluating the ideal delivery route and system also provides a benefit 345 
towards rational vaccine design. Investigating the mechanisms to overcome pre-existing 346 
immunity, an understanding of the basis for the stimulation of memory responses, and 347 
examining the interface between innate and adaptive immunity can also maximize the 348 
potential for vaccines to trigger long-lasting immunity and protection. 349 
 350 
Using ‘omics to catalyze and accelerate the decision process for the discovery of 351 
second generation vaccine candidate antigens 352 
 353 
Recent technology advancements of the 21st Century have allowed now the use of new 354 
animal or computer-based predictive models, biomarkers for safety and efficacy, and 355 
clinical evaluation techniques to assist in the improvement of predictability and efficacy 356 
needed along the critical path to move discoveries from the laboratory bench to 357 
licensure. Ultimately, developing and identifying methods to establish correlate markers 358 
or surrogate endpoints for protection will be necessary and essential [60]. 359 
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 360 
The current accumulation of molecular data and expansion of filarial parasite RNA and 361 
DNA databases, as well as proteomic datasets, has already provided a fresh start by 362 
permitting a more rational approach to vaccine candidate discovery [64]. For instance, 363 
the availability of genomes for B. malayi, L. sigmodontis and O. ochengi has facilitated 364 
numerous secretome studies across the parasite lifecycle [65-67]. One group of vaccine 365 
candidates that was identified by this unbiased, high-throughput approach was a ShK 366 
toxin domain family in which each individual member contains six ShK domains; a 367 
situation that is unique to filarial nematodes [30]. These abundant secreted proteins 368 
probably have an immunomodulatory role [66, 68] that could be targeted using antigens 369 
incorporating rational mutation of critical amino acid residue(s); an approach that has 370 
been used successfully with CPI-2 [56, 69]. In addition, the O. volvulus genome, as well 371 
as the transcriptome and proteome of each stage from the definitive host (L3, molting 372 
L3, L4, adult male, adult female, and nodule and skin microfilaria stages), has been 373 
published recently [70, 71]. These new datasets, when combined with immunomics [72-374 
76], have provided an opportunity to identify the antigens that, either alone or in 375 
combination, function as targets of natural acquired immunity against filariae. 376 
Recombinant protein or synthetic peptide arrays can be used to interrogate the 377 
genome-wide proteome of infectious pathogens consisting of the entire potential 378 
antigens using only small amounts of individual sera samples. This approach permits 379 
investigators to perform extensive longitudinal, epidemiological and surveillance 380 
analyses, as well as identifying immune responses at various stages of infections in the 381 
human host in a fashion not possible with other technologies [77, 78].  382 
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 383 
Using the immunomics approach with sera samples from putatively immune individuals 384 
from Cameroon and the Americas versus sera from infected individuals, six new 385 
potential vaccine antigens were identified. This was accomplished by screening for 386 
IgG1, IgG3 and IgE antibody responses against a protein array containing 362 O. 387 
volvulus recombinant proteins [71], and identifying those with a significant IgG1 and/or 388 
IgG3 reactivity with little-to-no IgE reactivity. Notably, four of these antigens 389 
(OVOC10819, OVOC5395, OVOC11598 and OVOC12235) are highly expressed during 390 
the development of the early stages of the infective stage larvae, L3, in the human host; 391 
these would be worthy candidates for testing their efficacy in a preventative vaccine 392 
model of infection. Interestingly, the two other proteins (OVOC8619 and OVOC7083) 393 
are highly expressed by the microfilariae and were mostly recognized by sera from the 394 
putatively immune individuals who never developed a patent infection with 395 
microfilaridermia; these would be worthy to be tested as vaccine candidates for a 396 
therapeutic vaccine [71].  397 
 398 
The initial objective for the Onchocerca vaccine was to identify candidate antigens for a 399 
prophylactic vaccine to be administered to children under the age of five who have not 400 
yet had access to MDA with ivermectin (Table 1); the first generation of our vaccine 401 
candidates fulfilled this objective. However, the immunomics approach now opens new 402 
possibilities for also developing a safe anti-transmission or therapeutic vaccine. The 403 
immunomics studies reported by Bennuru et al. [71] were the first time in which the O. 404 
volvulus stage-specific genome-wide expression data was used to discover empirically 405 
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novel vaccine candidates. It would be of great interest to test the novel vaccine 406 
candidates identified by the immunomics approach [71] in the O. volvulus diffusion 407 
chamber mouse model [45] and B. malayi – gerbil infection model to validate whether 408 
the immunomics approach actually have identified vaccine candidates that protect 409 
against L3 and/or microfilariae. 410 
 411 
Other potential applications of immunomic approaches include unbiased 412 
characterization of the immune response at the site of infection. In the O. ochengi 413 
system in cattle, a recent secretome analysis of nodule fluid identified almost 500 host 414 
proteins that ‘bathe’ the adult worms in vivo [67]. Interestingly, these proteins were 415 
dominated by antimicrobial proteins, such as cathelicidins, which probably originate 416 
from the neutrophils that dominate the intranodular environment. A parallel approach 417 
could be used to explore the immunological changes that occur within nodules in 418 
animals displaying partial protection induced by vaccination. Such studies will be very 419 
valuable in the future for the machine learning approach described below. 420 
 421 
Prospective: The potential for machine learning to accelerate the evaluation and 422 
selection of vaccine candidates 423 
 424 
Decades of research on prototype anti-filarial vaccines in animal models, the application 425 
of transgenic knockout mouse strains, and immunological studies of onchocerciasis 426 
patients presenting different clinical phenotypes, has led to a broad consensus on the 427 
characteristics of protective immunity and some of the key factors that drive 428 
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immunopathology. Thus, a Th2-biased immune response directed against incoming 429 
infective larvae, with a secondary (but important) role for a Th1 component and the 430 
modulating influence of T-regulatory cells, is associated with ‘benign’ protection [57, 79, 431 
80]. Conversely, at least in humans, unregulated Th2 responses against microfilariae in 432 
conjunction with Th17-driven inflammation and profound eosinophilia lead to effective 433 
parasite killing, but at the price of a hyperreactive form of onchocerciasis exhibiting 434 
severe skin inflammation also called sowda if the inflammation is unilaterally 435 
predominant  [81, 82]. This very rare condition is associated with certain genetic 436 
polymorphisms in immune-related genes [83, 84]. However, adverse reactions with a 437 
clear immunological component are possible in a wider range of patients, as is not 438 
uncommon with antifilarial chemotherapy [85, 86]. Consequently, accurately predicting 439 
whether a vaccine candidate is likely to be both safe and effective is very challenging 440 
using conventional approaches alone, especially as we lack animal models that 441 
recapitulate the pathology seen in human onchocerciasis.  442 
 443 
Traditional statistical approaches can be powerful at disentangling these immunological 444 
events, but tend not to generalize well from model systems to humans. However, 445 
machine learning techniques have been developed to improve generalizability by tuning 446 
models to maximize prediction accuracy to independent test samples, and tend to deal 447 
with large numbers of variables better than traditional statistical approaches [87, 88]. 448 
Such methods have been used successfully to analyze immune responses to bacterial 449 
infection using whole blood transcriptional signatures [89], and to detect local pathogen-450 
specific immune profiles in peritoneal dialysis patients [87]. In principle, by combining 451 
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vaccinology read-outs from animal models and natural immunity in humans, it may 452 
therefore be possible to improve the selection of vaccine candidates earlier than 453 
currently possible. Thus, by identifying robust markers of immunity that generalize well, 454 
such approaches may help bridge the divide between development, preclinical, and 455 
clinical phases of vaccine development (Fig. 2).  456 
 457 
Concluding remarks 458 
 459 
Although it was previously considered that O. volvulus infections can be controlled using 460 
only MDA with ivermectin, it is becoming increasingly clear that without additional 461 
modalities such as drugs which kill or permanently sterilize the adult worms and/or a 462 
vaccine, elimination of onchocerciasis from Sub Saharan Africa may remain an 463 
unfulfilled goal. Vaccines aimed at preventing infection (anti-L3), and/or reduce 464 
microfilariae in adults and children with onchocerciasis could be the essential 465 
complement for the successful control or elimination of both diseases. 466 
 467 
The successful vaccines developed against taeniases and the major advances already 468 
made in development of human anthelminthic vaccines [90], show that it is indeed 469 
possible to develop and test protective vaccines against multicellular parasites. In 470 
regard to O. volvulus, the human studies have suggested that protective immunity can 471 
develop in humans. The experimental and natural infections of calves have 472 
demonstrated that protective immunity does develop and that vaccines can protect 473 
animals from infection under natural conditions. Moreover, using the small animal 474 
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models for antigen screening have already accomplished the identification of two lead 475 
vaccine candidates; now the challenge is to optimize and formulate these vaccines for 476 
human usage, which can take advantage of the procedures currently being developed 477 
for the human hookworm and schistosome vaccines [91, 92], making the process 478 
potently quicker than usually expected (see Outstanding Questions). Efforts to develop 479 
novel diagnostic assay that support the monitoring of current and future control 480 
measures are underway and are expected to also provide in the near future diagnostic 481 
assays that can predict efficacy of the prophylactic and therapeutic vaccines in human 482 
clinical trials. 483 
 484 
The task ahead is to assure continued pre-clinical development by convincing potential 485 
donors that O. volvulus vaccine production and testing is a realistic goal worth 486 
supporting. The potential development of drug resistance to the drugs used for MDA 487 
and the many years of MDA now being anticipated to control onchocerciasis might 488 
provide such impetus.  489 
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Figure Legends: 499 
 500 
 501 
Figure 1: Schematics that illustrates the down-selection process that resulted in the 502 
selection of the two most promising vaccine antigens for future clinical development.  503 
 504 
 505 
Figure 2: Combining a systems analysis of response to vaccines and machine learning 506 
algorithms to help predict vaccine efficacy. (A) Applying machine learning to 507 
experimental infections across multiple model systems and species can help identify 508 
which immune variables throughout the time course of an infection most reliably predict 509 
infection load, while ensuring the trained models generalize well across biological 510 
systems. (B) These optimized models may then be useful in predicting vaccine efficacy 511 
in human trials in two ways: identifying what data to collect and predicting likely vaccine 512 
efficacy using incomplete data that are typical of human field studies.  513 
  514 
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 Table 1: Target product profiles for prophylactic and therapeutic onchocerciasis vaccines  
Characteristic Desired target – prophylactica 
Desired target – therapeutic 
(if different)b 
Indication 
A vaccine to protect against infection with infective 
larvae and to reduce adult worm burden and 
microfiladermia for the purpose of reducing 
morbidity and transmission 
A vaccine to reduce 
microfiladermia for the purpose 
of reducing morbidity and 
transmission 
Target population Children <5 years 
older children and adults that 
already carry adult worms 
Route of administration Intramuscular injection  
Product presentation Single-dose vials; <0.5 ml volume of delivery  
Dosage schedule Maximum of 3 immunizations given 4 weeks apart  
Warnings and 
precautions/pregnancy 
and lactation 
Mild to moderate local injection site reactions such 
as erythema, oedema and pain, the character, 
frequency, and severity of which is similar to 
licensed recombinant protein vaccines. Less than 
0.01% risk of urticaria and other systemic allergic 
reactions. Incidence of serious adverse reactions 
no more than licensed comparator vaccines 
 
Expected efficacy 
>50% efficacy at preventing establishment of 
incoming worms; >90% reduction of microfilariae 
(based on current animal model results) 
>99% reduction of microfilariae 
Co-administration 
All doses may be co-administered and/or used with 
other infant immunization programmes 
 
Shelf life 4 Years  
Storage 
Refrigeration between 2 to 8 degrees Celsius. 
Cannot be frozen. Can be out of refrigeration (at 
temperatures up to 25 degrees) for up to 72 hours 
 
Product registration 
Licensure by the Food and Drug Administration 
and/or the European Medicine Agency 
 
Target price 
Less than $10 per dose for use in low- and middle-
income countries. 
 
aadapted from [2]. 
Table 1- revised
 b, the assumptions for the blank cells are similar to those expected for the prophylactic vaccine 
Box 1: Key points that support the advancement and progress towards an 
onchocerciasis vaccine 
 It remains unlikely that onchocerciasis can be eliminated entirely through ivermectin 
mass treatments 
 An international consortium launched in 2015 a new global initiative, known as TOVA – 
The Onchocerciasis Vaccine for Africa –  with the goal of evaluating and pursuing 
vaccine development as a complementary control tool 
 A rational design for the antigen discovery and selection process before embarking into 
advanced vaccine development of the onchocerciasis vaccine resulted in the 
identification of two recombinant proteins – Ov-103 and Ov-RAL-2 – that individually or  
in combination induced significant protection against infection 
 
Trends Box
Outstanding Questions 
 
 What additional tools are needed to support the elimination of onchocerciasis in 
Africa? 
 Adjuvants are an important component for vaccine delivery; additional adjuvants 
that may increase efficacy should be tested versus alum formulated vaccines 
 The need to optimize the O. volvulus vaccine in regard to dosage, number of 
immunization and ability to provide sufficient memory 
 Should we proceed to identify new vaccine candidates for prophylactic and/or 
therapeutic vaccines using more rational approaches? 
 How can new technologies and artificial intelligence can catalyze and accelerate 
the evaluation and selection of more effective vaccine candidates leading to a 
greater chance of their translation into safe and efficacious human vaccines? 
 The development of diagnostic assays that can predict efficacy of the 
prophylactic and therapeutic vaccines in human clinical trials 
 
Outstanding Questions clean
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Responses to the reviewers’ critiques and editorial comments: 
 
Reviewer 1: 
 
This is an interesting and timely article on Onchocerca vaccines from a team that is at the 
cutting edge of this endeavour. The ms is reasonably well balanced but contains information 
that is a distraction to the main message, and lacks information on areas that I feel are critical 
for a balanced article. Specific comments are as follows. 
 
1. A figure outlining the different approaches to antigen discovery would be useful [COMMENT 
FROM THE EDITOR –Good suggestion from the reviewer. I would say that this figure would be 
more relevant than the current figure 1] 
 
Response: We decided to add a supplement table that outlines exactly how each vaccine 
protein was identified; hopefully that will fulfill the gap identified in Figure 1. 
 
2. The long list of antigens is too much like a laundry list and would be best captured as a table 
of vaccine antigens and their methods of discovery, percent efficacy in animal models, 
protective properties, adjuvants, etc. [COMMENT FROM THE EDITOR – Another good 
suggestion from the reviewer that should translate into an easier, more pleasant reading 
experience] 
 
Response: We have added a Supplement Table 1 that has the characteristics of all the 15 
antigens initially identified as potential vaccine candidates. Subsequently, we hope that 
ready the text is less of a laundry list and the reader can find more information on each 
protein with the relevant details on methods of discovery, percent efficacy in animal 
models, protective properties, adjuvants, etc. as suggested. 
 
3. On page 8, ranking of antigens is described; where is this information provided? It would be 
helpful for readers to see how ranking is done. 
 
Response: we appreciate the comment and consequently added a new text in the review 
that explain the ranking and the corresponding supplement table l that depicts the score 
given to each vaccine antigen.  
 
4. On page 8 there is brief mention of Th2 responses being required for protection. This is 
interesting and would benefit from expansion. Has vaccination in any filarial nematode been 
looked at in a setting where Th2 immunity is blocked, either genetically (Th2 deficient mice, 
eosinophil deficient mice?) or via neutralizing antibodies against Th2 cytokines, etc? 
 
Response: We thank the reviewer for raising this question. Indeed, the requirement for 
Th2 responses for adaptive immunity (naturally developing or vaccine-mediated) is 
consistent with evidence from immunity to O. volvulus in mice and other filarial models, 
and specifically, L. sigmodontis in which a full patent infection is possible in wild type 
BALB/c mice. A sentence with corresponding references has been added according. 
 
5. Some researchers believe that irradiated helminths will yield better protection than subunit 
vaccines, and there are already irradiated worm vaccines on the market for livestock filairiids 
(lungworm). Some discussion about irradiated flilarial parasites as vaccines is warranted. Has it 
Response to Reviewers
been done in an animal model for Oncho? Is (should) it be considered a gold standard in 
Oncho? Could sera from animals vaccinated with irradiated Oncho (or other filariids) be used to 
screen libraries or protein arrays? Can such an approach be feasibly scaled up for human use? 
 
Response: The reviewer rightly points out that irradiated infective larvae are an effective 
means to immunize against filarial infections. This has indeed been used in laboratory 
settings, mostly, and typically achieves around 70% protection, which has been shown in 
the O. volvulus and Litomosoides sigmodontis models to be mediated by the killing of 
larvae after infection. However, this approach cannot scale to veterinary or human 
vaccines (the lungworm Dictyocaulus viviparus is not, however, a filariid). A sentence 
has been added to the ms to address this. 
 
6. On page 12, the authors talk about 'filaria unique 6-ShK toxins domain family". They are Shk 
by definition (not a filariid) and they are found in many other species of nematodes. Can the 
author explain what they mean here? 
 
7. Two lines on from the ShK story the authors mention "rational ablation" and reference the 
term to a citation. Please explain herein what this actually means. 
 
Response to 6 and 7: an expansion on these family members of vaccine candidates in 
filaria was added including new references.  
 
Text now read: One group of vaccine candidates that was identified by this unbiased, 
high-throughput approach was a ShK toxin domain family in which each individual 
member contains six ShK domains; a situation that is unique to filarial nematodes [30]. 
These abundant secreted proteins probably have an immunomodulatory role [62, 64] that 
could be targeted using antigens incorporating rational mutation of critical amino acid 
residue(s); an approach that has been used successfully with CPI-2 [65, 66]. 
 
8. How many of your animal model-selected antigens matched those that obtained significant 
protection based on the proteome array studies when probed with endemic normal human 
subjects? 
 
Response: Good question. Interestingly, Ov103, Ov-RAL-2 and Ov-CPI-2 were part of the 
top 25 immunoreactive proteins recognized by the PI sera using the protein arrays. 
However, as in our recent publication we focused on the identification of potential novel 
vaccine candidates, we have selected to show just the six (OVOC10819, OVOC5395, 
OVOC11598, OVOC12235, OVOC8619, and OVOC7083) based on their IgG1 and/or IgG3 
reactivity (with little to no IgE reactivity), and subsequently discuss them in this review 
as 2nd generation of vaccine candidates. 
 
9. Page 14, para 1 (commencing "It is important to note...". This para is out of place here and 
should be moved elsewhere or deleted. [COMMENT FROM THE EDITOR – Could be moved to 
the concluding remarks section or see last comment by reviewer 2] 
 
Response: this paragraph was moved to the section “Evaluation and selection of the 
best vaccine candidates for a prophylactic vaccine using two small animal models” as 
suggested by Reviewer 2. 
 
10. The text from the bottom of page 16 through to the top of page 18 is somewhat off topic and 
too esoteric given the focus of the remainder of the article. I think this should be removed and 
replaced with more information on the development of resistance in humans (and animal 
models), including a focus on what is known about endemic normals and how they can guide 
antigen discovery and inform protective MoA. [COMMENT FROM THE EDITOR – I like the 
forward looking aspect of this section, but perhaps it can be turned into a more succinct text box 
on AI/machine learning, to leave room to address the reviewers suggestion] 
 
Response: we agree with the editor’s suggestion that this section should be shortened. 
We have reduced it to roughly a third of its original length, and removed the more 
technical explanations which the reader can now find in the references. We are not sure 
that this will fit into a text box; but it is up to the Editor to decide. 
 
11. The human infectious diseases field in general is moving towards human challenge models. 
eg. hookworm, malaria, and now the development (unpublished) of a human challenge model 
for schistosomiasis (male worms only). Is this feasible for Oncho? Some discussion around this 
would be good. Even if not feasible, discussion around how vaccine trials will assess efficacy in 
the field would be helpful. Has modelling been done for Oncho vaccines with and without 
chemotherapy? [COMMENT FROM THE EDITOR – Good points to address in the outstanding 
questions/concluding remarks] 
  
Response: For the cow model, we believe that the force of infection in Cameroon is 
sufficiently high so as not to require a challenge model.  Specifically, we think it's 
feasible to obtain both safety and efficacy signal immunizing cattle and looking at 
outcomes in a natural field setting.  For humans, we believe a similar situation may be 
in play. We could obtain an efficacy signal by conducting vaccine studies in an endemic 
setting.  To develop a challenge model and working out dose and routes (subcutaneous 
vs intradermal vs intramuscular) would require years of investigative work and may not 
be on the critical path. A minor change was made in the text, hope this will be 
satisfactory. 
 
 
Reviewer 2: 
 
The review of Onchocerca volvulus vaccines by Lustigman and colleagues is an interesting 
overview of current data. I have the following comments which may further add to their review: 
 
*          In the abstract, the authors state that resistance is probably developing - I think the 
authors need to be more definitive in this statement, is there evidence for drug resistance? 
 
Response: agree. We removed potential in the abstract and added in the text a new 
reference that describe recent genome-wide analyses which revealed genetic variation 
that significantly differentiated O. volvulus parasites that are good responders to 
treatment with ivermectin vs. sub-optimal responder (Doyle, SR et al 2017). 
 
*          Several of the sentences are particularly long, in some cases comprising an entire 
paragraph, making it difficult to take in all the information. If possible, these should be adapted 
into shorter sentences. 
 
Response: We have attempted to shorten some of the sentences as requested. 
 
*          Page 3 - the sentence 'Such estimates indicate that onchocerciasis may not be 
eliminated for decades using current approaches' requires a full stop. 
 
Response: done; thanks. 
 
*          Page 4 - can the author provide further information as to what classifies a protective 
immune response in terms of onchocerciasis. [COMMENT FROM THE EDITOR – Good 
suggestion from the reviewer to improve accessibility of the manuscript to the non-expert 
reader] 
 
Response: description of the anti-L3 protective immunity within the O. volvulus endemic 
population and in the mouse model was added to the text. 
 
*          Under the 'Evaluation and selection section..' - page 8 - the authors say that 15 proteins 
were evaluated from previous studies, yet the figure implies that 16 were used for further 
evaluation. 
 
Response: sorry about this confusion; one protein was cloned in 2005 by 
immunoscreening in addition to the 15 already identified in older previous studies, thus 
making the total 16. A sentence was added in the text to specify this. 
 
*          Page 8 the authors talk about the co administration of both antigens, but at this point in 
the paragraph it is not clear whether the O. volvulus antigens are being discussed or the B. 
malayi antigens or both. 
 
Response: This issue has been clarified in the text 
 
*          Page 8 - Remove the full stop between Escherichia and coli. 
 
Response: Done  
 
*          The sentence beginning 'Recent technology advancements of the 21st Century… (page 
11)' needs amending - the technology advances are not considering the use of new models and 
techniques; they have allowed the development and use of new tools. 
 
Response: thanks, the sentence was amended  
 
 
*          Page 13 - one of the objectives of the development of an Onchocerca vaccine is the 
potential use in children under the age of 5 that have not had access to MDA. Can the authors 
comment on the potential pitfalls/difficulties in developing a multi-use vaccine, in the sense of 
children and adults, particularly in relation to the adjuvant used to ensure the induction of a 
protective immune response? COMMENT FROM THE EDITOR – Excellent suggestion!] 
 
Response: we added a text that explain that the prophylactic vaccine for children is 
based on a mathematical modelling (Turner H et a; 2015), while the one for the 
therapeutic vaccine with a potential use in young and adults is still hypothetical as we 
will have to prove first that it will be safe to target microfilariae immunologically.  
 
 
*          The authors have included Table 1 that details the target product profiles for potential 
Onchocerca vaccines. What is this information based on? Has any mathematical modelling 
shown that for a vaccine to be effective in the current situation, that there should be a >50% 
reduction in worm establishment and a >90% reduction of microfilariae? How feasible is this 
with current candidate antigens? In short, what is this vaccine trying to achieve and against 
which lifecycle stage - an anti L3 vaccine? The authors also mention that the vaccine could treat 
adult and children with onchocerciasis - in what way? [COMMENT FROM THE EDITOR – If you 
find it helpful to address this comment, an additional column can be added to the table to cite 
relevant references] 
 
Response: we added a text that explain that the prophylactic vaccine in the TPP is based 
on a mathematical modelling (Turner H et a; 2015), while the one for the therapeutic 
vaccine is still hypothetical as we will have to prove first that it will be safe to target 
microfilariae immunologically.  
 
*          The authors review several studies that have identified various antigens of interest for 
vaccine trials, some which have been tested in animal models. The authors however, do not 
show how all these different antigens are related. Are the different methods of selection 
identifying similar antigens? Are they are all from the same lifecycle stage and if so what impact 
would that have on a potential vaccine? [COMMENT FROM THE EDITOR – I think the table 
suggested by reviewer 1 would also be helpful addressing this comment] Adjuvants are an 
important component for vaccine delivery - have any studies reported different efficacy levels in 
different adjuvants? [COMMENT FROM THE EDITOR – Perhaps another point to add to 
outstanding questions/concluding remarks] 
 
Response: As suggested by reviewer #1 and the Editor, we added a table (Supplement 1) 
that show all the 15 O. volvulus vaccine antigens, how they were identified and which 8 
were further selected based on scoring for extensive efficacy testing using the two 
animal models. 
 
We added another point to Outstanding Questions that addressed the need to compare 
efficacy of the vaccine when formulated with other adjuvants 
 
*          Have any studies been carried out investigating dosage schedules for vaccine delivery? 
Do 3 doses given 4 weeks apart provide sufficient memory responses? 
 
Response: Limited dosage studies have been performed at this time and it is unknown 
the duration of the memory response.   In fact these two areas will be the focus of future 
research. This point was added to Outstanding Questions. 
 
*          Details of the Litomosoides sigmodontis-BALB/c mouse model could be moved up to the 
other animal model section. 
  
Response: this paragraph was moved to the section “Evaluation and selection of the 
best vaccine candidates for a prophylactic vaccine using two small animal models” as 
suggested. 
 
  
Editorial Comments 
 
Line 51: Please add a sentence explaining how it is transmitted. I would also recommend 
adding a figure detailing the life cycle of the parasite.  
Response: a sentence was added regarding the transmission, 
 
I also referred to a supplement figure 1 that has the life cycle of O. volvulus taken for the 
CDC website. I added in a separated file the figure legend for this supplement figure alos 
taken from the same CDC website. Hope this is what you had in mind. 
 
Line 78: For non-specialist readers it should be explained what loiasis is and why co-endemicity 
is a problem. 
Response: a sentence to the reason why infection with the non-pathological Loa 
infection is a problem during MDA against Lymphatic filariasis and onchocerciasis was 
added.  
 
Line 165: You may want to add a brief conclusion here and a segue into the next section. 
Response: done, thanks. 
 
Line 174: diffusion chambers, please explain briefly what these are. 
Response: a sentence explaining the way diffusion cambers are used was added. 
 
Line 357: It would be interesting to know the symptoms/manifestations of this severe form of 
the disease. 
Response: a sentence explaining sowda clinical manifestation was added. 
 
Line 455: The outstanding questions box lists interesting, broad questions. I think our readers 
would also like to know your opinion on which specific 2-3 questions should be addressed in the 
next 5 years and how. You can add those to the outstanding questions box and discuss them 
further in the concluding remarks.  
Response: Thanks or this comment. We added three new outstanding questions as listed 
below as well as edited the conclusion section as needed. 
 
 Adjuvants are an important component for vaccine delivery; additional adjuvants 
that may increase efficacy should be tested versus alum formulated vaccines 
 The need to optimize the O. volvulus vaccine in regard to dosage, number of 
immunization and ability to provide sufficient memory 
 The development of diagnostic assays that can predict efficacy of the 
prophylactic and therapeutic vaccines in human clinical trials 
 
 
References: I would be grateful if you could: 
1. Italicize all genus and species names in the reference list - Done 
2. Provide full details for all references (30 and 36 seem to be incomplete; I was unable to find 
reference 7) 
Response: thanks for noting these gaps in the full citations 
 
Reference 7 was updated, it is now reference 14 
 
14. Sher, A. (1988) Vaccination against parasites: special problems imposed by the 
adaptation of parasitic organisms to the host immune response. In The Biology of 
Parasitism, eds. P.T. Englund & A. Sher, pp. 169-82. New York:, Alan R. Liss, Inc. 
 
Reference 30 was updated: it is now reference 66 
 
66. Armstrong, S.D. et al. (2014) Comparative Analysis of the Secretome from a Model 
Filarial Nematode (Litomosoides sigmodontis) reveals Maximal Diversity in Gravid 
Female Parasites. Mol Cell Proteomics. 13(10):2527-44  
 
Reference 36 was updated: it is now reference 71 
 
71. Bennuru, S. et al. (2016) Stage-Specific Transcriptome and Proteome Analyses of 
the Filarial Parasite Onchocerca volvulus and Its Wolbachia Endosymbiont. MBio 7 (6). 
pii: e02028-16. 
 
 
Table 1: Please include the table in the revised version of the main manuscript. 
 
When cells are left blank, what does that mean? Please clarify using a footnote. 
 
Response: A footnote was added saying that the assumptions for the blank cells are 
similar to those in the column of prophylactic vaccine  
 
Was the full table adapted from this publication or only this column? Please clarify in a reply to 
this comment.  
 
Response: many thanks for noticing this; you are right, only the column of prophylactic 
vaccine was adapted and the column on therapeutic vaccine is new. 
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Outstanding Questions 
 
 What additional tools are needed to support the elimination of onchocerciasis in 
Africa? 
 Adjuvants are an important component for vaccine delivery; additional adjuvants 
that may increase efficacy should be tested versus alum formulated vaccines 
 The need to optimize the O. volvulus vaccine in regard to dosage, number of 
immunization and ability to provide sufficient memory 
 Should we proceed to identify new vaccine candidates for prophylactic and/or 
therapeutic vaccines using more rational approaches? 
 How can new technologies and artificial intelligence can catalyze and accelerate 
the evaluation and selection of more effective vaccine candidates leading to a 
greater chance of their translation into safe and efficacious human vaccines? 
 The development of diagnostic assays that can predict efficacy of the 
prophylactic and therapeutic vaccines in human clinical trials 
 
Outstanding Questions
